Quest Diagnostics Settles $13M Kickback Allegations Linked to Giants Tickets
Quest Diagnostics has reached a settlement of over $13 million to resolve allegations that it provided illegal kickbacks to healthcare providers and executives through New York Giants tickets and access to exclusive events. This settlement, announced by the U.S. Attorney’s Office for New Jersey, highlights significant concerns regarding the integrity of medical referrals and the potential corruption of medical judgment.
According to U.S. Attorney Robert Frazer, the clinical laboratory operator based in Secaucus, New Jersey, allegedly offered clients suite seats at Giants games and access to training camps in exchange for business referrals. This practice is a clear violation of the Anti-Kickback Statute, which prohibits any form of payment that encourages the use of services covered by Medicare, Medicaid, and other federally funded healthcare programs.
Explore on Amazon
Amazon shopping links. As an Amazon Associate I earn from qualifying purchases.
Frazer emphasized the detrimental effects of such kickbacks, stating, "Kickbacks to referring providers, especially by lab companies, corrupt medical judgment, lead to unnecessary lab testing, cause providers to steer patients to labs that offer inducements, and squander taxpayer money." The allegations suggest that between July 25, 2013, and August 3, 2022, Quest Diagnostics not only violated the kickback statute but also submitted false claims for lab services that were reimbursed by Medicare and state Medicaid programs.
The relationship between Quest and the New York Giants began in 2013 when the lab entered into a sponsorship agreement that granted it naming rights and various marketing benefits. As part of this arrangement, Quest received access to luxury suites for home games at MetLife Stadium, which it used to entertain clients. Prosecutors allege that after entertaining these clients, Quest calculated the revenue generated from them for up to a year, subsequently billing Medicare and Medicaid for lab tests referred by those clients.
Corporate Integrity Measures Enforced
The New York Giants organization has not responded to requests for comment regarding these allegations. In addition to the financial settlement, Quest Diagnostics is required to implement a five-year corporate integrity agreement with the Department of Health and Human Services' Office of Inspector General. This agreement mandates that the company engage an independent review organization to conduct audits of its operations.
The Part Nobody Mentioned
Despite the settlement, a spokesperson for Quest stated that the firm denies any wrongdoing, asserting that it agreed to the settlement to resolve the matter and move forward. Amanda Rivera, a spokesperson for Quest, emphasized the company’s commitment to compliance with laws and regulations governing its business practices, noting that the Corporate Integrity Agreement reflects their existing compliance program.
The implications of this settlement extend beyond Quest Diagnostics, raising questions about the integrity of healthcare referrals and the enforcement of regulations designed to protect public funds. As the healthcare industry continues to grapple with issues of transparency and ethical conduct, this case serves as a reminder of the potential for corruption and the importance of stringent oversight in healthcare practices.




